Saturday, November 2, 2024
HomeTagsTyrosine kinase inhibitor

tyrosine kinase inhibitor

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or...

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for repotrectinib, a next-generation tyrosine...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics